-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NLAlvMlKIpYXPenHYjZuMTSy2I23euUNGJWOV67CP3HpYsbDJzdlN96ArK+U/HCG
 YP05ItSdtziZItImE5+/mA==

<SEC-DOCUMENT>0001209191-09-012160.txt : 20090227
<SEC-HEADER>0001209191-09-012160.hdr.sgml : 20090227
<ACCEPTANCE-DATETIME>20090227160811
ACCESSION NUMBER:		0001209191-09-012160
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090225
FILED AS OF DATE:		20090227
DATE AS OF CHANGE:		20090227

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Gordon Eric M
		CENTRAL INDEX KEY:			0001413009

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33730
		FILM NUMBER:		09643014

	BUSINESS ADDRESS:	
		BUSINESS PHONE:		6504750149

	MAIL ADDRESS:	
		STREET 1:		C/O SKYLINE VENTURES
		STREET 2:		UNIVERSITY AVENUE SUITE 520
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Targanta Therapeutics Corp.
		CENTRAL INDEX KEY:			0001398161
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203971077
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		222 THIRD AVENUE
		STREET 2:		SUITE 2300
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(617) 557-9020

	MAIL ADDRESS:	
		STREET 1:		222 THIRD AVENUE
		STREET 2:		SUITE 2300
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>c81840_4x0.xml
<DESCRIPTION>MAIN DOCUMENT DESCRIPTION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2009-02-25</periodOfReport>

    <notSubjectToSection16>1</notSubjectToSection16>

    <issuer>
        <issuerCik>0001398161</issuerCik>
        <issuerName>Targanta Therapeutics Corp.</issuerName>
        <issuerTradingSymbol>TARG</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001413009</rptOwnerCik>
            <rptOwnerName>Gordon Eric M</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O TARGANTA THERAPEUTICS CORP.</rptOwnerStreet1>
            <rptOwnerStreet2>222 THIRD STREET</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02142</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2009-02-25</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>U</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>12599</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote.</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2009-02-25</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>U</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>505998</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote.</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2009-02-25</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>U</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>1699311</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote.</value>
                    <footnoteId id="F4"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">The shares were tendered in a tender offer by Boxford Subsidiary Corporation for consideration of (1) $2.00 per common share in cash, plus (2) the contractual right to receive up to an additional $4.55 per common share in contingent cash payments if specified regulatory and commercial milestones are achieved within agreed upon time periods.</footnote>
        <footnote id="F2">Shares held by Skyline Venture Partners III, L.P., whose General Partner is Skyline Venture Management III, LLC.  John Freund and Yasunori Kaneko, as Managing Directors of Skyline Venture Management III, LLC, may be deemed to share voting and dispositive power with respect to all common stock and warrants to purchase common stock held by Skyline affiliated entities.  In addition, Eric Gordon is a partner at Skyline ventures, and as such has influence in the voting and investment power of these shares, although he has no direct power.  Each of Drs. Freund, Kaneko and Gordon disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any.</footnote>
        <footnote id="F3">Shares held by Skyline Venture Partners Qualified Purchaser Fund III, L.P., whose General Partner is Skyline Venture Management III, LLC.  John Freund and Yasunori Kaneko, as Managing Directors of Skyline Venture Management III, LLC, may be deemed to share voting and dispositive power with respect to all common stock and warrants to purchase common stock held by Skyline affiliated entities.  In addition, Eric Gordon is a partner at Skyline ventures, and as such has influence in the voting and investment power of these shares, although he has no direct power.  Each of Drs. Freund, Kaneko and Gordon disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any.</footnote>
        <footnote id="F4">Shares held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P., whose General Partner is Skyline Venture Management IV, LLC.  John Freund and Yasunori Kaneko, as Managing Directors of Skyline Venture Management IV, LLC, may be deemed to share voting and dispositive power with respect to all common stock and warrants to purchase common stock held by Skyline affiliated entities.  In addition, Eric Gordon is a partner at Skyline ventures, and as such has influence in the voting and investment power of these shares, although he has no direct power.  Each of Drs. Freund, Kaneko and Gordon disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Mark Leuchtenberger, by power of attorney</signatureName>
        <signatureDate>2009-02-26</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----